PharmaLectures.com

Courses › Pharma training by role › Regulatory affairs: everything Europe expects of you, in one course

Regulatory affairs: everything Europe expects of you, in one course

Your European dossiers clear validation the first time, so the launch date holds.

Pharmaceutical regulatory affairs is the function that obtains and maintains the marketing authorisations a medicine needs to be sold. In the European Union the core law is Directive 2001/83/EC and Regulation (EC) No 726/2004, which set out the centralised, decentralised, mutual recognition and national procedures. After approval, regulatory teams file variations under Regulation (EC) No 1234/2008, handle renewals, keep the dossier in Common Technical Document format current, and work with pharmacovigilance and quality. Your team gets everything Europe expects of regulatory affairs staff in one course.

  • 10 audio modulesthree lengths each
  • 1 h 40 min to 8 h 20 minbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • Regulatory affairswho it is written for

Why pharmaceutical regulatory affairs training matters

At the European Medicines Agency's validation check, a Module 1 document is missing from your centralized application. The assessment clock does not start. Your team rebuilds the dossier while the launch slips and a competitor files first.

What changes after this course

Your team picks the right procedure before the first page is written, builds the Common Technical Document to the validation checklist and classifies each change correctly. You hold a certificate for every learner and a training record for each person.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

Pharmaceutical regulatory affairs training: what this course gives your people

Your team decides the submission route in the meeting where the product is discussed, not three emails later. The Annex to Regulation (EC) No 726/2004 and the legal bases in Directive 2001/83/EC become a short checklist. You know whether the product goes to the European Medicines Agency, or to a reference member state under the decentralized or mutual recognition procedure.

The dossier comes together right the first time. Module 1 carries the administrative documents the national authority checks, Module 3 holds the quality data an assessor looks for first, and the Module 2 summaries tell the clinical story. When a site changes equipment, you classify the change as Type IA, Type IB or Type II under Regulation (EC) No 1234/2008 in one conversation.

Safety and inspection questions get answers on the spot. An inspector asks for the Pharmacovigilance System Master File, and your Qualified Person for Pharmacovigilance can show how it matches the real system. Individual case safety reports and periodic safety update reports go out on time, and batch release records are ready before the Good Manufacturing Practice inspector asks.

Renewals and long-term planning stop depending on one person's memory. Your team files the renewal at least nine months before the five-year mark, tracks the sunset clause for each authorization, and asks the European Medicines Agency for scientific advice before a development choice is locked. Advanced therapy and Brexit questions get a clear route.

Who needs pharmaceutical regulatory affairs training

  • Regulatory Affairs Associate

    Your manager asks whether the dossier is ready for validation. You open Module 1, check each administrative document against the checklist and answer yes, with the evidence in your hand.

  • Senior Regulatory Affairs Specialist

    A site swaps a filling line on Tuesday. By lunch you have classified the change under Regulation (EC) No 1234/2008 and told production whether it can go ahead before approval.

  • Pharmacovigilance Manager

    An inspector from a national competent authority asks for the Pharmacovigilance System Master File. You hand it over current, and the Qualified Person for Pharmacovigilance can explain each section.

  • Regulatory Lifecycle Manager

    Commercial stops selling a slow product. You work out the sunset clause date the same day and warn the team before the authorization lapses.

Roles: Regulatory affairs

Businesses: every kind of pharma company

Countries: India, China, Türkiye, Korea, Japan, Taiwan, Egypt, Gulf and MENA, Brazil and Latin America, Pakistan, Bangladesh and Vietnam, United States, Europe

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Select the legal basis for a marketing authorization application under Directive 2001/83/EC and decide whether Regulation (EC) No 726/2004 requires the centralized procedure.
  2. Choose between the decentralized and mutual recognition procedures for a product and name the right reference member state.
  3. Check a Common Technical Document, including Module 1 and Module 3, against the validation checklist before it is sent.
  4. Classify a post-authorization change as Type IA, Type IB or Type II under Regulation (EC) No 1234/2008.
  5. Calculate the renewal deadline and the date a sunset clause could end an authorization.
  6. Prepare the Pharmacovigilance System Master File evidence a Qualified Person needs to answer an inspector.
  7. Write a briefing document that asks the European Medicines Agency a question it can answer.

What the company gets

  • Your dossiers leave the building checked against one validation list, so a missing document does not hold up the launch.
  • Every manufacturing change is filed under the right variation type, so supply is not stopped by a wrong classification.
  • Your inspector gets straight answers on the Pharmacovigilance System Master File and safety reporting from the people who run it.
  • Renewal and sunset clause dates sit in one tracked list, so no authorization lapses because nobody watched the calendar.
  • You hold a certificate for each learner and a training record per person, ready when an auditor asks who was trained.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 10 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing1 h 40 min10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard4 h 10 min25 min a module, for regulatory, quality and business-development staff
Expanded8 h 20 min50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Regulatory affairsStandard4 h 10 min

Pharmaceutical regulatory affairs course outline: 10 modules

10 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Choose your legal basis under Directive 2001/83/EC and Regulation 726/2004

    • Why the Annex to Regulation (EC) No 726/2004 decides which products must be filed centrally.
    • How to pick between a full, generic or well-established use application under Directive 2001/83/EC.
    • What to do when your product qualifies for the centralized route but does not have to use it.
  2. 2File a centralized application the European Medicines Agency can validate

    • When the 210-day assessment clock stops, and what your team must send before it restarts.
    • Why you tell the Agency your intended submission date months ahead, and how to request rapporteurs.
    • The checks the Agency runs on your application before the clock starts, and how to pass them in one go.
  3. 3Choose between decentralized and mutual recognition for each product

    • How to choose the reference member state that carries your decentralized procedure.
    • When mutual recognition is the faster route, because a first national authorization already exists.
    • What to do when a concerned member state raises a potential serious risk to public health.
  4. 4Build a Common Technical Document that passes European validation

    • How to fill Module 1 so the national authority does not bounce the dossier for a missing form.
    • What to check in Module 3 quality sections before the electronic Common Technical Document goes out.
    • The Module 2 summaries that let an assessor find your clinical argument in minutes.
  5. 5Classify every variation under Regulation (EC) No 1234/2008

    • How to sort a site change into Type IA, IB or II using the Commission classification guideline.
    • When you may implement a change first and notify after, and when you must wait for approval.
    • What to do when a Type II variation needs clinical data you do not yet have.
  6. 6Submit renewals on time and track the sunset clause on each authorization

    • Why the renewal application is due at least nine months before the five-year authorization expires.
    • How the sunset clause ends an authorization after three years without a product on the market.
    • What goes into the consolidated file that shows the benefit-risk balance is still positive.
  7. 7Keep your Pharmacovigilance System Master File aligned with European rules

    • What the Qualified Person for Pharmacovigilance needs in the master file to answer an inspector.
    • The individual case safety report deadlines for serious and non-serious cases, and who starts the clock.
    • What a periodic safety update report must show so assessors can judge the benefit-risk balance.
  8. 8Pass Good Manufacturing Practice inspections without critical findings

    • How inspectors grade a finding as critical, major or other, and what pushes it up a grade.
    • What to do in the days before an inspection, so batch release records and quality systems hold up.
    • Why a data integrity gap in batch records can turn a routine visit into a critical finding.
  9. 9Request scientific advice from the European Medicines Agency before you file

    • How to write the briefing document so the Scientific Advice Working Party answers the question you asked.
    • When to ask for advice and when not to, so the answer is one you can build a programme on.
    • Why departing from a Committee for Medicinal Products for Human Use guideline needs written justification.
  10. 10Adapt submissions for advanced therapy medicinal products and Brexit

    • How the advanced therapy medicinal product rules in Regulation (EC) No 1394/2007 change your dossier.
    • Why the Committee for Advanced Therapies drafts the opinion your application then depends on.
    • How Brexit puts the United Kingdom on its own submission route, apart from the European Union filing.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about pharmaceutical regulatory affairs training

What does a regulatory affairs professional do in pharma?

Regulatory affairs staff plan the route to approval, compile and submit the dossier, answer questions from agencies, and keep the authorisation valid after approval through variations, renewals and safety updates. They also check that labels, packaging and promotional claims match what was approved, and advise other departments on what a planned change will require. In Europe they work with the EMA and national agencies.

What is the sunset clause for EU marketing authorisations?

Under EU law a marketing authorisation ceases to be valid if the product is not actually placed on the market within three years of authorisation, or if a product already marketed is absent from the market for three consecutive years. Agencies can grant exemptions in exceptional cases on public health grounds. Regulatory teams track these dates so authorisations are not lost by accident.

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

10 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 1 h 40 min in the briefing length and 8 h 20 min in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for Regulatory affairs. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 90 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team